Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Subunit and Virus-Like Particle Vaccine Approaches for Respiratory Syncytial Virus

  • Chapter
  • First Online:
Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 372))

Abstract

Despite its impact on global health, there is no vaccine available for the prevention of respiratory syncytial virus (RSV) infection. Failure to develop a licensed vaccine is not due to lack of effort, as numerous vaccine candidates have been characterized in preclinical and clinical studies spanning five decades. The vaccine candidates thus far explored can be generally divided into four categories: (1) whole inactivated virus, (2) replication competent, attenuated virus including recombinant viruses, (3) gene-based vectors, and (4) subunit and particulate forms of RSV antigens. The first clinically tested RSV vaccine candidate was a formalin-inactivated purified virus preparation administered to infants and children in the late 1960s. Due to the disastrous outcome of these trials and results of animal models investigating the mechanisms involved, there have been no further studies with inactivated RSV vaccines. Rather, efforts have focused on development of other approaches. In this chapter, we review the history and status of purified proteins, peptides, virus-like particles, virosomes, and nanoparticles and discuss their future potential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Belshe RB, Anderson EL, Walsh EE (1993) Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 168:1024–1029

    Article  CAS  PubMed  Google Scholar 

  • Bessa J, Kopf M, Bachmann MF (2010) Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 184:4615–4619

    Article  CAS  PubMed  Google Scholar 

  • Calder LJ, Gonzales-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA (2000) Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122–131

    Article  CAS  PubMed  Google Scholar 

  • Cardenas S, Auais A, Piedimonte G (2005) Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3:719–726

    Article  CAS  PubMed  Google Scholar 

  • Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA (2012) Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol 25:193–203

    CAS  PubMed  Google Scholar 

  • Collins PL, Crowe JE (2007) Respiratory syncytial virus and metapneumovirus, 5th edn. LippincottWilliams and Wilkins, Philadelphia

    Google Scholar 

  • Collins PL, Graham BS (2007) Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82:2040–2055

    Article  PubMed Central  PubMed  Google Scholar 

  • Connors M, Collins PL, Firestone C-Y, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR (1992) Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia RSV recombinants or RSV. Vaccine 10:475–484

    Article  CAS  PubMed  Google Scholar 

  • de Waal L, Power UF, Yuksel S, van Amerongen G, Nguyen TN, Niesters HGM, de Swart RL, Osterhaus ADME (2004) Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22:915–922

    Article  PubMed  Google Scholar 

  • Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang H-Y, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP (2009) Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34–41

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749–1759

    Article  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE (1996) Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14:1214–1218

    Article  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE (1997) Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15:1130–1132

    Article  CAS  PubMed  Google Scholar 

  • Falsey AR, Walsh EE (2000) Respiratory syncytial virus infection in adults. Clin Microbiol Rev 13:371–384

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simoes EAF, Wright PF, Sales VM-P (2008) Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 198:1317–1326

    Article  PubMed  Google Scholar 

  • Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock REW, Babiuk LA, Gerdts V, Potter A, van Drunen Littel-van den Hurk S (2012) Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 30:5206–5214

    Google Scholar 

  • Graham BS (2012) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149–166

    Article  Google Scholar 

  • Grgacic EVL, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60–65

    Article  CAS  PubMed  Google Scholar 

  • Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EAF (1998) Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 177:467–469

    Article  CAS  PubMed  Google Scholar 

  • Guay HM, Andreyeva TA, Garcea RL, Welsh RM, Szomolanyi-Tsuda E (2007) MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol 178:5124–5131

    CAS  PubMed  Google Scholar 

  • Hall CB (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344:1917–1928

    Article  CAS  PubMed  Google Scholar 

  • Han LL, Alexander JP, Anderson LJ (1999) Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179:25–30

    Article  CAS  PubMed  Google Scholar 

  • Hildreth SW, Baggs RR, Brownstein DG, Castleman WL, Paradiso PR (1993) Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at (3–6) months after immunization. Vaccine 11:615–618

    Article  CAS  PubMed  Google Scholar 

  • Hussell T, Baldwin CJ, O’Garra A, Openshaw PJM (1997) CD8 + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 27:3341–3349

    Article  CAS  PubMed  Google Scholar 

  • Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJM (1998) Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 161:6215–6222

    CAS  PubMed  Google Scholar 

  • Jennings GT, Bachmann MF (2008) The coming of age of virus-like particle vaccines. J Biol Chem 389:521–536

    CAS  Google Scholar 

  • Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A (2012) Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a in mice. PLoS ONE 7:e36812

    Google Scholar 

  • Kang S-M, Song J-M, Quan F-S, Compans RW (2009) Influenza vaccines based on virus-like particles. Virus Res 143:140–146

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Karron RA (2008) Respiratory syncytial virus and parainfluenza virus vaccines, 5th edn. Saunders-Elsevier, Philadelphia

    Google Scholar 

  • Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543–547

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kwilas S, Liesman RM, Zhang L, Walsh E, Pickles RJ, Peeples ME (2009) Respiratory syncytial virus grown in vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol 83:10710–10718

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lambrecht BN, Kool M, Willart MAM, Hammad H (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21:23–29

    Article  CAS  PubMed  Google Scholar 

  • Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E (2009) A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults greater than or equal to 65 years of age. Vaccine 27:5913–5919

    Article  CAS  PubMed  Google Scholar 

  • Lanzavecchia A, Sallusto F (2007) Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 19:268–274

    Article  CAS  PubMed  Google Scholar 

  • Lanzavecchia A, Sallusto F (2009) Human B cell memory. Curr Opin Immunol 21:298–304

    Article  CAS  PubMed  Google Scholar 

  • Latham T, Galarza JM (2001) Formation of wild type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75:6154–6165

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ludwig C, Wagner R (2007) Virus-like particles–universal molecular toolboxes. Curr Opin Biotechnol 18:537–545

    Article  CAS  PubMed  Google Scholar 

  • Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci 109:3089–3094

    Article  CAS  PubMed  Google Scholar 

  • McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG (2011) Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 85:366–377

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG (2010) Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol 84:4513–4523

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McLellan JS, Yang Y, Graham BS, Kwong PD (2011) Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788–7796

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM (2009) Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab’)2 components mediated reduced pulmonary inflammation in mice. J Gen Virol 90:1119–1123

    Article  CAS  PubMed  Google Scholar 

  • Munoz FM, Piedra PA, Glezen WP (2003) Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21:3465–3467

    Article  CAS  PubMed  Google Scholar 

  • Murata Y (2009) Respiratory syncytial virus vaccine development. Clin Lab Med 29:725–739

    Article  PubMed Central  PubMed  Google Scholar 

  • Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare M, Smith G, Heaton PM, Fraire A, Morrison TG (2010) Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice with no evidence of immunopathology. J Virol 84:1110–1123

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, Lawrence L, Zubak JJ, Chanock RM, Beeler JA, Prince GA (1989) Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7:533–540

    Article  CAS  PubMed  Google Scholar 

  • Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine 8:497–502

    Article  CAS  PubMed  Google Scholar 

  • Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EAF, Rudan I, Weber MW, Campbell H (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet 375:1545–1555

    Article  Google Scholar 

  • Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nguyen TN, Power UF, Robert A, J-Fo Haeuw, Helffer K, Perez A, Asin M-A, Corvaia N, Libon C (2012) The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents. PLoS ONE 7:e34331

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Oien NL, Brideau RJ, Thomsen DR, Homa FL, Wathen MW (1993) Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 11:1040–1048

    Article  CAS  PubMed  Google Scholar 

  • Oien NL, Brideau RJ, Walsh EE, Wathen MW (1994) Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12:731–735

    Article  CAS  PubMed  Google Scholar 

  • Openshaw PJ, Tregoning JS (2005) Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18:541–555

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pantua HD, McGinnes LW, Peeples ME, Morrison TG (2006) Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol 80:11062–11073

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Paradiso PRP, Hildreth SWD, Hogerman DA, Speelman DJ, Lewin EBM, Oren JM, Smith DHM (1994) Safety and immunogenicity of a subunit respiratory syncytial virus vacine in children 24 to 48 months old. Pediatr Infect Dis J 13:792–798

    Article  CAS  PubMed  Google Scholar 

  • Pasare C, Medzhitov R (2005) Control of B-cell responses by Toll-like receptors. Nature 438:364–368

    Article  CAS  PubMed  Google Scholar 

  • Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW (2003) Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21:2448–2460

    Article  CAS  PubMed  Google Scholar 

  • Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR (1995) Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 13:1095–1101

    Article  CAS  PubMed  Google Scholar 

  • Power UF (2008) Respiratory syncytial virus (RSV) vaccines–two steps back for one leap forward. J Clin Virol 41:38–44

    Article  CAS  PubMed  Google Scholar 

  • Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus ADME, de Groot R, Corvaia N, Beck A, Bouveret-le-Cam N, Bonnefoy J-Y (2001) Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184:1456–1460

    Article  CAS  PubMed  Google Scholar 

  • Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12:509–517

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Quan F-S, Kim Y, Lee S, Yi H, Kang S-M, Bozja J, Moore ML, Compans RW (2011) Virus-like particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 204:987–995

    Article  CAS  PubMed  Google Scholar 

  • Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413–424

    Article  PubMed Central  PubMed  Google Scholar 

  • Remot A, Roux X, Dubuquoy C, Fix J, Bouet S, Moudjou M, Eleouet J-F, Riffault S, Petit-Camurdan A (2012) Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PLoS ONE 7:e37722

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Roux X, Dubuquoy C, Durand G, Tran-Tolla T-L, Castagne N, Bernard J, Petit-Camurdan A, Eleouet J-F, Riffault S (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS ONE 3:e1766

    Article  PubMed Central  PubMed  Google Scholar 

  • Schmidt MR, Appel MC, Giassi LJ, Greiner DL, Shultz LD, Woodland RT (2008) Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice. PLoS ONE 3:e3192

    Article  PubMed Central  PubMed  Google Scholar 

  • Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG (2012) Long term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 86:11654–11662

    Google Scholar 

  • Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118–130

    Article  CAS  PubMed  Google Scholar 

  • Simard C, Nadon F, Seguin C, Trudel M (1995) Evidence that the amino acid region 124–203 of glycoprotein G from the respiratory synctial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection. Antiviral Res 28:303–315

    Article  CAS  PubMed  Google Scholar 

  • Simoes EAF, Tan DHS, Ohlsson A, Sales V, Wang EEL (2001) Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 20:954–960

    Article  CAS  PubMed  Google Scholar 

  • Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 28:5543–5550

    Article  CAS  PubMed  Google Scholar 

  • Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29:3341–3355

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108:9619–9624

    Article  CAS  PubMed  Google Scholar 

  • Teng MN, Collins PL (1998) Identification of respiratory syncytial virus proteins required for formation and passage of helper dependent infectious particles. J Virol 72:5707–5716

    CAS  PubMed Central  PubMed  Google Scholar 

  • Thompson W, Shay DK, Weintraub E et al (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179–186

    Article  PubMed  Google Scholar 

  • Tripp RA (2004) Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17:165–181

    Article  CAS  PubMed  Google Scholar 

  • Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732–738

    Article  CAS  PubMed  Google Scholar 

  • Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P (1993) Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 167:191–195

    Article  CAS  PubMed  Google Scholar 

  • Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331–3334

    Article  CAS  PubMed  Google Scholar 

  • Trudel M, Nadon F, Seguin C, Binz H (1991) Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 185:749–757

    Article  CAS  PubMed  Google Scholar 

  • Walsh EE, Falsey AR, Hennessey PA (1999) Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med 160:791–795

    Article  CAS  PubMed  Google Scholar 

  • Yin H-S, Paterson RG, Wen X, Lamb RA, Jardetzky TS (2005) Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci U S A 102:9288–9293

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yin H-S, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38–44

    Article  CAS  PubMed  Google Scholar 

  • Zhang L, Kovalev GI, Su L (2007) HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109:2978–2981

    CAS  PubMed  Google Scholar 

  • Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA (2010) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus g protein reduces pulmonary inflammation and virus replication in mice. J Virol 84:1148–1157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng P-Y, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK (2012) Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008. Clin Infect Dis 54:1427–1436

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, 01655, USA

    Trudy G. Morrison

  2. Division of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester General Hospital, Rochester, NY, 14621, USA

    Edward E. Walsh

Authors
  1. Trudy G. Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward E. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trudy G. Morrison .

Editor information

Editors and Affiliations

  1. Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA

    Larry J. Anderson

  2. Vaccine Research Center, NIH Natl. Inst. of Allergy & Infect. Dis., Bethesda, Maryland, USA

    Barney S. Graham

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Morrison, T.G., Walsh, E.E. (2013). Subunit and Virus-Like Particle Vaccine Approaches for Respiratory Syncytial Virus. In: Anderson, L., Graham, B. (eds) Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, vol 372. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38919-1_14

Download citation

Publish with us

Policies and ethics

Search

Navigation